Shenzhen Chipscreen Biosciences Co Ltd is a China-based company mainly engaged in the research and development of original innovative drugs. The Company focuses on the research and development of original innovative drugs in five therapeutic areas, including malignant tumors, metabolic diseases, autoimmune diseases, central nervous system diseases and anti-virus. The Company's main products include Chidamide, Siglitazone, Cioroni and CS12192. The Company mainly conducts its businesses in the domestic market.

Employees

1,060

Sector

Pharmaceuticals

Calendar

Mar. 30 - Q4 2025 Earnings Release

More about the company

Quotes

Date	Price	Change	Volume
26-02-10	31.76 ¥	+1.28%	9,533,967
26-02-09	31.36 ¥	+1.10%	6,004,385
26-02-06	31.02 ¥	-0.29%	7,021,050
26-02-05	31.11 ¥	-1.08%	6,696,673
26-02-04	31.45 ¥	+0.96%	8,444,707

End-of-day quote Shanghai S.E.

More quotes

Income Statement and Estimates

More financial data

Annual profits - Rate of surprise

Company calendar

End-of-day quote Shanghai S.E. Other stock markets 2026-02-10			5-day change	1st Jan Change
31.76 ^CNY	+1.28%		+1.96%	+8.69%

Jan. 27	Shenzhen Chipscreen Biosciences Expects Return to Profitability in 2025	MT
Jan. 09	Chipscreen Biosciences Gets Nod for Xioronni Capsules' Clinical Trials	MT

Capitalization	11.92B 1.72B 1.45B 1.32B 1.26B 2.33B 156B 2.44B 15.34B 6.11B 75.24B 6.47B 6.33B 266B	P/E ratio 2023	101x	P/E ratio 2024	-66.2x
Enterprise value	12.4B 1.79B 1.51B 1.37B 1.31B 2.43B 162B 2.54B 15.95B 6.36B 78.26B 6.73B 6.59B 277B	EV / Sales 2023	17.5x	EV / Sales 2024	12.2x
Free-Float	61.11%	Yield 2023 *	-	Yield 2024	-

Jan. 27	Shenzhen Chipscreen Biosciences Expects Return to Profitability in 2025	MT
Jan. 09	Chipscreen Biosciences Gets Nod for Xioronni Capsules' Clinical Trials	MT
Jan. 08	Shenzhen Chipscreen Biosciences Gets Macao Marketing Approval for Cancer Drug	MT
Jan. 02	Chinese Drug Regulator Accepts Clinical Trial Application of Chipscreen Biosciences' Unit for CS08399 Tablets	MT
Dec. 23	Tranche Update on Shenzhen Chipscreen Biosciences Co., Ltd.'s Equity Buyback Plan announced on October 31, 2025.	CI
Dec. 22	Shenzhen Chipscreen Biosciences Co., Ltd.'s Equity Buyback announced on October 31, 2025, has closed with 538,200 shares, representing 0.13% for CNY 15 million.	CI
Nov. 07	Shenzhen Chipscreen Biosciences Gets Clinical Trial Approval for Pancreatic Cancer Treatment	MT
25-10-31	Shenzhen Chipscreen Biosciences Co., Ltd. announces an Equity Buyback for CNY 15 million worth of its shares.	CI
25-10-30	Shenzhen Chipscreen Biosciences Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2025	CI
25-10-29	Shenzhen Chipscreen Biosciences Co., Ltd. authorizes a Buyback Plan.	CI
25-09-10	Chipscreen Biosciences' shareholder to unload stake in co	RE
25-08-25	Shenzhen Chipscreen Biosciences Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2025	CI
25-08-01	Chipscreen Bio's US Unit Gets FDA Nod for Anti-Brain Tumor Drug	MT

23-02-28	Biocytogen's Subsidiary Eucure Biopharma and Chipscreen Biosciences Holding Subsidiary Chipscreen NewWay Biosciences Enter into Greater China License Agreement for Bispecific Antibody YH008	AQ
23-02-27	Biocytogen’s Subsidiary Eucure Biopharma and Chipscreen Biosciences’ Holding Subsidiary Chipscreen NewWay Biosciences Enter into Greater China License Agreement for Bispecific Antibody YH008	BU

Shenzhen Chipscreen Biosciences Co., Ltd. Stock

Equities

688321

CNE100003LW0

Pharmaceuticals

Valuation: Shenzhen Chipscreen Biosciences Co., Ltd.

Chart: Shenzhen Chipscreen Biosciences Co., Ltd.

Latest news: Shenzhen Chipscreen Biosciences Co., Ltd.

Analysts' recommendations: Shenzhen Chipscreen Biosciences Co., Ltd.

Press Releases: Shenzhen Chipscreen Biosciences Co., Ltd.

News in other languages: Shenzhen Chipscreen Biosciences Co., Ltd.

Quotes and Performance

Course Extremes

Managers and Directors: Shenzhen Chipscreen Biosciences Co., Ltd.

Specialty & Advanced Pharmaceuticals

Financials

Company Profile

Quotes

Income Statement and Estimates

Annual profits - Rate of surprise

1 day	+1.28%
1 week	+1.96%
Current month	-0.78%
1 month	-7.41%
3 months	+5.41%
6 months	-8.74%
Current year	+8.69%

1 week	30.75	32.47
1 month	30.33	36.47
Current year	29.15	36.47
1 year	14.86	44.99
3 years	12.47	44.99
5 years	12.47	47.76
10 years	12.47	125

Manager	Title	Age	Since
Zhi Qiang Ning CTO	Chief Tech/Sci/R&D Officer	66	2001-04-30
Xian Ping Lu CEO	Chief Executive Officer	63	2018-03-23
Jian Xun Li DFI	Director of Finance/CFO	55	2001-05-31

Director	Title	Age	Since
Xian Ping Lu CHM	Chairman	63	2018-03-23
Jian Xun Li BRD	Director/Board Member	55	2018-03-23
Ou Hai BRD	Director/Board Member	48	2018-03-23

	2023	2024
Net sales	524M 75.78M 63.68M 58.06M 55.44M 103M 6.86B 107M 674M 269M 3.31B 284M 278M 11.69B	658M 95.21M 80M 72.94M 69.65M 129M 8.62B 135M 847M 337M 4.15B 357M 350M 14.68B
Net income	88.84M 12.86M 10.8M 9.85M 9.4M 17.4M 1.16B 18.18M 114M 45.55M 561M 48.22M 47.22M 1.98B	-115M -16.58M -13.93M -12.7M -12.13M -22.44M -1.5B -23.45M -147M -58.74M -723M -62.19M -60.9M -2.56B
Net Debt	228M 33.03M 27.75M 25.3M 24.16M 44.71M 2.99B 46.71M 294M 117M 1.44B 124M 121M 5.09B	480M 69.39M 58.31M 53.16M 50.77M 93.94M 6.28B 98.14M 617M 246M 3.03B 260M 255M 10.7B

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5d. change	1-year change	3-years change	Capi.($)
SHENZHEN CHIPSCREEN BIOSCIENCES CO., LTD.	+1.28%	+1.96%	+72.05%	+9.37%	1.87B
MERCK KGAA	-0.84%	+0.57%	-7.95%	-33.25%	64.96B
HALOZYME THERAPEUTICS, INC.	-0.32%	+4.89%	+39.90%	+63.98%	9.43B
KYOWA KIRIN CO., LTD.	+9.79%	+13.20%	+25.19%	-13.70%	8.83B
SK BIOPHARMACEUTICALS CO., LTD.	+1.73%	-3.04%	-10.51%	+60.81%	6B
YUHAN CORPORATION	+0.84%	+0.09%	-20.44%	+115.99%	5.52B
INDIVIOR PHARMACEUTICALS, INC.	-1.18%	-5.61%	+250.73%	+38.52%	4.18B
MEZZION PHARMA CO.,LTD.	+2.92%	-3.31%	+419.52%	+1,066.92%	3.16B
SUPERNUS PHARMACEUTICALS, INC.	-0.23%	+5.74%	+34.93%	+32.35%	2.93B
BETTA PHARMACEUTICALS CO., LTD.	+1.27%	+3.04%	-18.98%	-25.29%	2.91B
Average	+1.53%	+2.19%	+78.44%	+131.57%	10.98B
Weighted average by Cap.	+0.50%	+2.77%	+22.44%	+26.45%